NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
The drug maker is selling most of its stake in a joint venture with Shanghai Pharmaceuticals for $608 million By Teri Yu Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), the biopharmaceutical…
Recent Articles
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
